Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Double-Dose HIV drug tested to keep virus in check during TB treatment

NCT ID NCT05630872

Summary

This study tested if taking a double dose of the HIV medication dolutegravir is safe and effective when used alongside a specific tuberculosis (TB) treatment. Researchers wanted to see if the higher dose would keep HIV levels low, as the TB drug can interfere with the HIV medication. The trial involved 30 adults with both HIV and newly diagnosed TB who were not yet on HIV treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-ASSOCIATED TUBERCULOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Durban International CRS (Site # 11201)

    Westridge, Durban RSA, 4091, South Africa

  • South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793)

    Worcester, Western Province, 6850, South Africa

  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802)

    Bangkok, 6850, Thailand

  • University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792)

    Mowbray, Cape Town, Western Cape, 7700, South Africa

Conditions

Explore the condition pages connected to this study.